UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations

Clinical and translational science, 2023-12, Vol.16 (12), p.2675-2686

2023

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies

Clinical pharmacokinetics, 2019-06, Vol.58 (6), p.727-746

2019

Volltextzugriff (PDF)

Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors

Antimicrobial Agents and Chemotherapy, 2012-06, Vol.56 (6), p.3144-3156

2012

Volltextzugriff (PDF)

Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration

Clinical pharmacokinetics, 2024-04, Vol.63 (4), p.483-496

2024

Volltextzugriff (PDF)

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

Clinical cancer research, 2022-07, Vol.28 (14), p.3002-3010

2022

Volltextzugriff (PDF)

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Cancer discovery, 2023-08, Vol.13 (8), p.1789-1801

2023

Volltextzugriff (PDF)

Physiologically based pharmacokinetic (PBPK) modeling: science and applications

1, 2005

Volltextzugriff (PDF)

Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans

Xenobiotica, 2016-08, Vol.46 (8), p.667-676

2016

Volltextzugriff (PDF)

Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics: Results of Computer-Based Simulations and a Clinical Drug-Drug Interaction Study

Clinical pharmacokinetics, 2012-07, Vol.51 (7), p.457-465

2012

Volltextzugriff (PDF)

Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics

Clinical pharmacokinetics, 2012-07, Vol.51 (7), p.457

2012

Volltextzugriff (PDF)

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible

Biopharmaceutics & drug disposition, 2011-07, Vol.32 (5), p.261-275

2011

Volltextzugriff (PDF)

Peat porewater chloride concentration profiles in the Everglades during wet/dry cycles from January 1996 to June 1998: field measurements and theoretical analysis

Hydrological processes, 2008-05, Vol.22 (11), p.1713-1724

2008

Volltextzugriff (PDF)

Characterization of surface and ground water δ18O seasonal variation and its use for estimating groundwater residence times

Hydrological processes, 2006-05, Vol.20 (8), p.1753-1772

2006

Volltextzugriff (PDF)

Assessing Kinetic Determinants for Metabolism and Oral Uptake of Octamethylcyclotetrasiloxane (D4) from Inhalation Chamber Studies

Inhalation toxicology, 2008-01, Vol.20 (4), p.361-373

2008

Volltextzugriff (PDF)

Closed-Chamber Inhalation Pharmacokinetic Studies with Hexamethyldisiloxane in the Rat

Inhalation toxicology, 2003-05, Vol.15 (6), p.589-617

2003

Volltextzugriff (PDF)

Abstract CT178: Phase 1 trial of PF-07799933 (ARRY-440), a next-generation BRAF inhibitor, for BRAF-mutant cancers

Cancer research (Chicago, Ill.), 2024-04, Vol.84 (7_Supplement), p.CT178-CT178

2024

Volltextzugriff (PDF)

Further Comments on the Bioavailability of D4

Environmental health perspectives, 2002-08, Vol.110 (8), p.A444-A445

2002

Volltextzugriff (PDF)

Reply to comment on 'Characterization of surface and ground water δ18O seasonal variation and its use for estimating groundwater residence times' by R. E. Criss and W. E. Winston

Hydrological processes, 2006-10, Vol.20 (16), p.3573-3578

2006

Volltextzugriff (PDF)

Reply to comment on ‘Characterization of surface and ground water δ 18 O seasonal variation and its use for estimating groundwater residence times’ by R. E. Criss and W. E. Winston

Hydrological processes, 2006-10, Vol.20 (16), p.3573-3578

2006

Volltextzugriff (PDF)

Characterization of surface and ground water delta18O seasonal variation and its use for estimating groundwater residence times

Hydrological processes, 2006-05, Vol.20 (8), p.1753-1772

2006

Volltextzugriff (PDF)

Characterization of surface and ground water [delta] super(18)O seasonal variation and its use for estimating groundwater residence times

Hydrological processes, 2006-01, Vol.20 (8), p.1753-1772

2006

Volltextzugriff (PDF)

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible: DANOPREVIR REGIONAL DRUG BIOAVAILABILITY ASSESSMENT

Biopharmaceutics & drug disposition, 2011-07, Vol.32 (5), p.261-275

2011

Volltextzugriff (PDF)

Dermal Exposure Models

Physiologically Based Pharmacokinetic Modeling, 2005, p.375-387

2005

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Modeling

Preclinical Development Handbook, 2008, p.1167-1227

2008

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Aktive Filter

KollektionIngenta.com

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(42)

Publikationsform

Sprache

Englisch
(51)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of posaconazole and diltiazem on pharmacokinetics of encorafenib, a BRAF V600 kinase inhibitor for melanoma and colorectal cancer with BRAF mutations

Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies

Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors

Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation

Physiologically based pharmacokinetic (PBPK) modeling: science and applications

Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans

Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics: Results of Computer-Based Simulations and a Clinical Drug-Drug Interaction Study

Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible

Peat porewater chloride concentration profiles in the Everglades during wet/dry cycles from January 1996 to June 1998: field measurements and theoretical analysis

Characterization of surface and ground water δ18O seasonal variation and its use for estimating groundwater residence times

Assessing Kinetic Determinants for Metabolism and Oral Uptake of Octamethylcyclotetrasiloxane (D4) from Inhalation Chamber Studies

Closed-Chamber Inhalation Pharmacokinetic Studies with Hexamethyldisiloxane in the Rat

Abstract CT178: Phase 1 trial of PF-07799933 (ARRY-440), a next-generation BRAF inhibitor, for BRAF-mutant cancers

Further Comments on the Bioavailability of D4

Reply to comment on 'Characterization of surface and ground water δ18O seasonal variation and its use for estimating groundwater residence times' by R. E. Criss and W. E. Winston

Reply to comment on ‘Characterization of surface and ground water δ 18 O seasonal variation and its use for estimating groundwater residence times’ by R. E. Criss and W. E. Winston

Characterization of surface and ground water delta18O seasonal variation and its use for estimating groundwater residence times

Characterization of surface and ground water [delta] super(18)O seasonal variation and its use for estimating groundwater residence times

Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible: DANOPREVIR REGIONAL DRUG BIOAVAILABILITY ASSESSMENT

Dermal Exposure Models

Physiologically Based Pharmacokinetic Modeling

Aktive Filter

Suchergebnisse filtern